专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07045532B2 ACE-2 modulating compounds and methods of use thereof 失效
标题翻译： ACE-2调节化合物及其使用方法
公开(公告)号：US07045532B2
公开(公告)日：2006-05-16
申请号：US09999781
申请日：2001-10-31
申请人： Susan L. Acton , Timothy D. Ocain , Alexandra E. Gould , Natalie A. Dales , Bing Guan , James A. Brown , Michael Patane , Vivek J. Kadambi , Michael Solomon , Alain Stricker-Krongrad
发明人： Susan L. Acton , Timothy D. Ocain , Alexandra E. Gould , Natalie A. Dales , Bing Guan , James A. Brown , Michael Patane , Vivek J. Kadambi , Michael Solomon , Alain Stricker-Krongrad
IPC分类号： A61K31/194 , A61K31/198 , A61K31/39 , A61K31/415 , A61K31/4172
CPC分类号： C07D231/12 , A61K31/00 , A61K31/195 , A61K31/196 , A61K31/341 , A61K31/36 , A61K31/381 , A61K31/40 , A61K31/4035 , A61K31/4164 , A61K31/42 , A61K31/421 , A61K31/422 , A61K31/426 , A61K31/433 , A61K31/44 , A61K31/4439 , C07B2200/07 , C07C229/16 , C07C229/24 , C07C229/26 , C07C229/36 , C07C271/20 , C07C275/24 , C07C323/52 , C07C323/58 , C07C2601/02 , C07C2601/14 , C07D209/20 , C07D213/55 , C07D233/64 , C07D235/16 , C07D249/08 , C07D261/08 , C07D277/06 , C07D277/30 , C07D277/40 , C07D277/42 , C07D333/24 , C07D405/06 , C07K16/40
摘要： ACE-2 inhibitors for the treatment of body weight and related disorders are disclosed. ACE-2 inhibitors include peptides and small molecules. Examples of small molecule ACE-2 inhibitors include compounds of formula (I): Z-Λ (I) Wherein Z is a zinc coordinating moiety and Λ is an amino-acid mimicking moiety, and pharmaceutically acceptabale salts thereof. Methods of using the inhibitors and pharmaceutical compositions containing the inhibitors to treat a body weight disorder, to decrease appetite, to increase muscle mass, to decrease body fat, to treat diabetes and to treat a state associated with altered lipid metabolism, are also described.
摘要翻译：公开了用于治疗体重和相关疾病的ACE-2抑制剂。 ACE-2抑制剂包括肽和小分子。小分子ACE-2抑制剂的实例包括式（I）的化合物：<？in-line-formula description =“In-line formula”end =“lead”？> Z-Lambda（I） formula description =“In-line Formulas”end =“tail”？>其中Z是锌配位部分，Lambda是氨基酸模拟部分及其药学上可接受的盐。还描述了使用抑制剂和含有抑制剂的药物组合物治疗体重紊乱，降低食欲，增加肌肉量，降低体脂肪，治疗糖尿病和治疗与脂质代谢改变相关的状态的方法。

2. 发明授权

US06429289B1 Class BI and CI scavenger receptors 失效
标题翻译： BI和CI清道夫受体
公开(公告)号：US06429289B1
公开(公告)日：2002-08-06
申请号：US08265428
申请日：1994-06-23
申请人： Monty Krieger , Susan L. Acton , Alan M. Pearson
发明人： Monty Krieger , Susan L. Acton , Alan M. Pearson
IPC分类号： C07K14705
CPC分类号： C07K14/705 , A61K38/00
摘要： Two distinct scavenger receptor type proteins having high affinity for modified lipoproteins and other ligands have been isolated, characterized and cloned. HaSR-BI, an AcLDL and LDL binding scavenger receptor, which is distinct from the type I and type II macrophage scavenger receptors, has been isolated and characterized and DNA encoding the receptor cloned from a variant of Chinese Hamster Ovary Cells, designated Var-261. dSR-CI, a non-mammalian AcLDL binding scavenger receptor having high ligand affinity and broad specificity, was isolated from Drosophila melanogaster. The isolated receptors are useful in screening for drugs that inhibit uptake of cholesterol in endothelial or adipose cells or macrophages, respectively. They are also useful as probes for the isolation of other lipoprotein receptors and in research the roles of these receptors.
摘要翻译：已经分离，表征和克隆了对修饰的脂蛋白和其它配体具有高亲和力的两种不同的清道夫受体型蛋白质。已经分离和表征与I型和II型巨噬细胞清道夫受体不同的AcLDL和LDL结合清道夫受体的HaSR-BI，并编码从中国仓鼠卵巢细胞变体克隆的受体的DNA，命名为Var-261 。从黑腹果蝇中分离出具有高配体亲和力和广泛特异性的非哺乳动物AcLDL结合清道夫受体的dSR-CI。分离的受体可用于筛选分别抑制内皮细胞或脂肪细胞或巨噬细胞中胆固醇摄取的药物。它们也可用作分离其他脂蛋白受体的探针和研究这些受体的作用。

3. 发明授权

US07001753B2 59079 and 12599, protein kinase family members and uses therefor 失效
公开(公告)号：US07001753B2
公开(公告)日：2006-02-21
申请号：US10077130
申请日：2002-02-15
申请人： Rosana Kapeller-Libermann , Susan L. Acton
发明人： Rosana Kapeller-Libermann , Susan L. Acton
IPC分类号： C12N9/20 , C12N15/00 , C12N1/20 , C12Q1/68 , C07H21/04
CPC分类号： C12N9/1205 , A01K2217/05 , A61K38/00 , C07K2319/00
摘要： The invention provides isolated nucleic acids molecules, designated 59079 and 12599 nucleic acid molecules, which encode novel protein kinase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 59079 or 12599 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 59079 or 12599 gene has been introduced or disrupted. The invention still further provides isolated 59079 and 12599 proteins, fusion proteins, antigenic peptides and anti-59079 and anti-12599 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

4. 发明授权

US06740737B2 Cardiovascular system associated protein kinase 2 (CSAPK-2) antibodies 失效
标题翻译：心血管系统相关蛋白激酶2（CSAPK-2）抗体
公开(公告)号：US06740737B2
公开(公告)日：2004-05-25
申请号：US09757982
申请日：2001-01-10
申请人： Susan L. Acton
发明人： Susan L. Acton
IPC分类号： C07K1600
CPC分类号： G01N33/5005 , A01K2217/05 , A61N1/3655 , C07K2319/00 , C12N9/1205 , C12Q1/48 , C12Q1/485 , G01N33/5008 , G01N33/5014 , G01N33/502 , G01N33/68 , G01N33/6893 , G01N2500/00 , G01N2800/32
摘要： The invention provides isolated nucleic acids molecules, designated CSAPK nucleic acid molecules, which encode novel protein kinases. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing CSAPK nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a CSAPK gene has been introduced or disrupted. The invention still further provides isolated CSAPK proteins, fusion proteins, antigenic peptides and anti-CSAPK antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
摘要翻译：本发明提供编码新型蛋白激酶的分离的核酸分子，命名为CSAPK核酸分子。本发明还提供反义核酸分子，含有CSAPK核酸分子的重组表达载体，其中引入了表达载体的宿主细胞，以及其中引入或破坏了CSAPK基因的非人类转基因动物。本发明还进一步提供了分离的CSAPK蛋白，融合蛋白，抗原肽和抗CSAPK抗体。还提供了利用本发明组合物的诊断，筛选和治疗方法。

5. 发明授权

US5925333A Methods for modulation of lipid uptake 失效
标题翻译：调节脂质摄取的方法
公开(公告)号：US5925333A
公开(公告)日：1999-07-20
申请号：US559505
申请日：1995-11-15
申请人： Monty Krieger , Susan L. Acton , Attilio Rigotti , Helen Haskell Hobbs , Katherine Tallman Landschulz
发明人： Monty Krieger , Susan L. Acton , Attilio Rigotti , Helen Haskell Hobbs , Katherine Tallman Landschulz
IPC分类号： C12N15/09 , A61K31/00 , A61K31/56 , A61K31/565 , A61K35/76 , A61K38/00 , A61K38/22 , A61K45/00 , A61K48/00 , A61P3/00 , A61P3/06 , C07K14/705 , C12N15/00 , C12N15/12 , C12N15/85 , C12N15/79
CPC分类号： C12N15/8509 , C07K14/705 , A01K2217/05 , A01K2227/105 , A01K2267/025 , A01K2267/03 , A01K2267/0362 , A61K38/00 , A61K48/00 , C12N2799/022
摘要： Methods for regulation of lipid and cholesterol uptake are described which are based on regulation of the expression or function of the SR-BI HDL receptor. The examples demonstrate that estrogen dramatically downregulates SR-BI under conditions of tremendous upregulation of the LDL-receptor. The examples also demonstrate the upregulation of SR-BI in rat adrenal membranes and other non-placental steroidogenic tissues from animals treated with estrogen, but not in other non-placental non-steroidogenic tissues, including lung, liver, and skin. Examples further demonstrate the uptake of fluorescently labeled HDL into the liver cells of animal, which does not occur when the animals are treated with estrogen.
摘要翻译：描述了调节脂质和胆固醇摄取的方法，其基于调节SR-BI HDL受体的表达或功能。这些实施例证明雌激素在LDL-受体大量上调的条件下显着下调SR-BI。这些实施例还证明了在用雌激素治疗的动物的大鼠肾上腺膜和其它非胎盘类固醇生成组织中SR-BI的上调，但在其他非胎盘非类固醇生成组织（包括肺，肝脏和皮肤）中的上调。实施例进一步证明了将荧光标记的HDL摄取到动物的肝细胞中，当用雌激素治疗时不会发生。

6. 发明授权

US06632830B1 ACE-2 inhibiting compounds and methods of use thereof 失效
标题翻译： ACE-2抑制化合物及其使用方法
公开(公告)号：US06632830B1
公开(公告)日：2003-10-14
申请号：US09561759
申请日：2000-04-28
申请人： Susan L. Acton , Timothy D. Ocain , Alexandra E. Gould , Natalie A. Dales , Bing Guan , James A. Brown
发明人： Susan L. Acton , Timothy D. Ocain , Alexandra E. Gould , Natalie A. Dales , Bing Guan , James A. Brown
IPC分类号： A61K31194
CPC分类号： C07D231/12 , C07B2200/07 , C07C229/16 , C07C229/24 , C07C229/26 , C07C229/36 , C07C271/20 , C07C275/24 , C07C323/52 , C07C323/58 , C07C2601/02 , C07C2601/14 , C07D209/20 , C07D213/55 , C07D233/64 , C07D235/16 , C07D249/08 , C07D261/08 , C07D277/06 , C07D277/30 , C07D277/40 , C07D277/42 , C07D333/24 , C07D405/06
摘要： ACE-2 inhibiting compounds are disclosed. These compounds include compounds of formula (IV): wherein the variables are as described in the specification. Pharmaceutical compositions containing the compounds are also discussed. The pharmaceutical compositions may contain an effective amount of a compound of the invention to treat ACE-2 associated disorders such as a blood pressure related disease or disorder, cell proliferation disorder, kidney disorder, kinetensin associated disorder, inflammation associated disorder, or an allergic disorder.
摘要翻译：公开了ACE-2抑制化合物。这些化合物包括式（IV）的化合物：其中变量如说明书中所述。还讨论了含有这些化合物的药物组合物。药物组合物可以含有有效量的本发明化合物以治疗ACE-2相关疾病，例如与血压相关的疾病或病症，细胞增殖病症，肾脏疾病，激素相关病症，炎症相关疾病或过敏性疾病。

7. 发明授权

US06610497B1 Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor 失效
标题翻译：血管紧张素转换酶同系物及其治疗和诊断用途
公开(公告)号：US06610497B1
公开(公告)日：2003-08-26
申请号：US09407427
申请日：1999-09-29
申请人： Susan L. Acton , Keith Earl Robison , Frank Y. Hsieh
发明人： Susan L. Acton , Keith Earl Robison , Frank Y. Hsieh
IPC分类号： G01N3353
CPC分类号： A61K38/4813 , C12N9/48 , C12Y304/15001
摘要： The present invention relates to the discovery of novel genes encoding an angiotensin converting enzyme, Angiotensin Converting Enzyme-2 (ACE-2). The invention provides therapeutics, prognostic and diagnostics methods for treating blood pressure related disorders as well as various types of allergic conditions, among others. Also disclosed are screening assays for identifying compounds for treating and preventing these conditions.
摘要翻译：本发明涉及编码血管紧张素转换酶血管紧张素转化酶-2（ACE-2）的新基因的发现。本发明提供了用于治疗血压相关疾病以及各种类型的变态反应病症的治疗，预后和诊断方法。还公开了用于鉴定用于治疗和预防这些病症的化合物的筛选测定。

8. 发明授权

US06228581B1 Human intronic and polymorphic SR-BI nucleic acids and uses therefor 失效
标题翻译：身体质量和心血管疾病的诊断测定和试剂盒
公开(公告)号：US06228581B1
公开(公告)日：2001-05-08
申请号：US09031626
申请日：1998-02-27
申请人： Susan L. Acton , Jose M. Ordovas
发明人： Susan L. Acton , Jose M. Ordovas
IPC分类号： C12Q168
CPC分类号： C12Q1/6883 , C12Q2600/156 , C12Q2600/172
摘要： The present invention is based at least in part on the discovery of the genomic structure of the human SR-BI gene and on the identification of polymorphic regions within the gene. Accordingly, the invention provides nucleic acids having a nucleotide sequence of an allelic variant of an SR-BI gene and nucleic acids having an SR-BI intronic sequence. The invention also provides methods for identifying specific alleles of polymorphic regions of an SR-BI gene, methods for determining whether a subject has or is at risk of developing a disease which is associated with a specific allele of a polymorphic region of an SR-BI gene, and kits for performing such methods.
摘要翻译：本发明至少部分地基于人SR-BI基因的基因组结构的发现和基因中多态性区域的鉴定。因此，本发明提供具有SR-BI基因的等位基因变体的核苷酸序列和具有SR-BI内含子序列的核酸的核酸。本发明还提供用于鉴定SR-BI基因的多态性区域的特异性等位基因的方法，用于确定受试者是否具有发生与SR-BI的多态性区域的特定等位基因相关的疾病的风险的方法基因和用于进行这些方法的试剂盒。

9. 发明授权

US07268218B2 Cardiovascular system associated protein kinase 3 (CSAPK-3) antibodies 失效
标题翻译：心血管系统相关蛋白激酶3（CSAPK-3）抗体
公开(公告)号：US07268218B2
公开(公告)日：2007-09-11
申请号：US10786501
申请日：2004-02-25
申请人： Susan L. Acton
发明人： Susan L. Acton
IPC分类号： C07K16/00 , G01N33/53
CPC分类号： G01N33/5005 , A01K2217/05 , A61N1/3655 , C07K2319/00 , C12N9/1205 , C12Q1/48 , C12Q1/485 , G01N33/5008 , G01N33/5014 , G01N33/502 , G01N33/68 , G01N33/6893 , G01N2500/00 , G01N2800/32
摘要： The invention provides isolated nucleic acids molecules, designated CSAPK nucleic acid molecules, which encode novel protein kinases. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing CSAPK nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a CSAPK gene has been introduced or disrupted. The invention still further provides isolated CSAPK proteins, fusion proteins, antigenic peptides and anti-CSAPK antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
摘要翻译：本发明提供编码新型蛋白激酶的分离的核酸分子，称为CSAPK核酸分子。本发明还提供反义核酸分子，含有CSAPK核酸分子的重组表达载体，其中引入了表达载体的宿主细胞，以及其中引入或破坏了CSAPK基因的非人类转基因动物。本发明还进一步提供了分离的CSAPK蛋白，融合蛋白，抗原肽和抗CSAPK抗体。还提供了利用本发明组合物的诊断，筛选和治疗方法。

10. 发明授权

US06989363B1 Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor 失效
公开(公告)号：US06989363B1
公开(公告)日：2006-01-24
申请号：US09163648
申请日：1998-09-30
申请人： Susan L. Acton , Keith Earl Robison , Frank Y. Hsieh
发明人： Susan L. Acton , Keith Earl Robison , Frank Y. Hsieh
IPC分类号： C07K14/00 , C07K14/435
CPC分类号： A61K38/4813 , A61K38/00 , C12N9/48 , C12Y304/15001
摘要： The present invention relates to the discovery of novel genes encoding an angiotensin converting enzyme, Angiotensin Converting Enzyme-2 (ACE-2). The invention provides therapeutics, prognostic and diagnostics methods for treating blood pressure related disorders as well as various types of allergic conditions, among others. Also disclosed are screening assays for identifying compounds for treating and preventing these conditions.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式